Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial

Overview of attention for article published in BMC Cancer, November 2015

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (54th percentile)

So far, Altmetric has seen 1 public wall post.

【前立腺がん】骨転移例において標準療法であるアンドロゲン除去療法に「フェアストン®」を加えた併用療法の、5年PSA無再燃率は100%であった。ちなみにアンドロゲン除去療法単独では30%、「エビスタ®」併用療法では53%。〔BMC Cancer〕 http:…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.